DZ2200A1 - Compositions pour un traitement une fois par jour des maladies ayant pour mediateur la 2-cyclooxygenase. - Google Patents

Compositions pour un traitement une fois par jour des maladies ayant pour mediateur la 2-cyclooxygenase.

Info

Publication number
DZ2200A1
DZ2200A1 DZ970087A DZ970087A DZ2200A1 DZ 2200 A1 DZ2200 A1 DZ 2200A1 DZ 970087 A DZ970087 A DZ 970087A DZ 970087 A DZ970087 A DZ 970087A DZ 2200 A1 DZ2200 A1 DZ 2200A1
Authority
DZ
Algeria
Prior art keywords
cyclooxygenase
compositions
once daily
diseases mediated
daily treatment
Prior art date
Application number
DZ970087A
Other languages
English (en)
Inventor
Barry Gertz
Bruno Hancock
Ellot Ehrich
Conrad Winters
Original Assignee
Merck & Co Inc
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ2200(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9612063.9A external-priority patent/GB9612063D0/en
Application filed by Merck & Co Inc, Merck Frosst Canada Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DZ2200A1 publication Critical patent/DZ2200A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
DZ970087A 1996-05-17 1997-05-14 Compositions pour un traitement une fois par jour des maladies ayant pour mediateur la 2-cyclooxygenase. DZ2200A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1787896P 1996-05-17 1996-05-17
GBGB9612063.9A GB9612063D0 (en) 1996-06-10 1996-06-10 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases

Publications (1)

Publication Number Publication Date
DZ2200A1 true DZ2200A1 (fr) 2004-06-20

Family

ID=26309472

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ970087A DZ2200A1 (fr) 1996-05-17 1997-05-14 Compositions pour un traitement une fois par jour des maladies ayant pour mediateur la 2-cyclooxygenase.

Country Status (28)

Country Link
US (1) US6063811A (fr)
EP (1) EP0910368A1 (fr)
JP (1) JPH11512754A (fr)
KR (1) KR100373622B1 (fr)
CN (1) CN1140267C (fr)
AR (1) AR012014A1 (fr)
AU (1) AU3004997A (fr)
BG (1) BG103000A (fr)
BR (1) BR9709097A (fr)
CA (1) CA2254061C (fr)
CO (1) CO5050370A1 (fr)
CZ (1) CZ291463B6 (fr)
DZ (1) DZ2200A1 (fr)
EA (1) EA001596B1 (fr)
EE (1) EE03746B1 (fr)
HR (1) HRP970262A2 (fr)
HU (1) HUP9902889A3 (fr)
ID (1) ID16921A (fr)
IL (1) IL126899A (fr)
IS (1) IS4891A (fr)
MY (1) MY116201A (fr)
NO (1) NO985342D0 (fr)
NZ (1) NZ332670A (fr)
PE (1) PE66998A1 (fr)
PL (1) PL188649B1 (fr)
SK (1) SK284330B6 (fr)
TR (1) TR199802345T2 (fr)
WO (1) WO1997044028A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
WO1999045913A1 (fr) * 1998-03-13 1999-09-16 Merck & Co., Inc. Therapie associee destinee au syndrome ischemique coronarien aigu ainsi qu'a des troubles connexes
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
CN1434713A (zh) * 1999-12-22 2003-08-06 法马西亚公司 环加氧酶-2抑制剂的缓释制剂
ATE511844T1 (de) 2000-06-13 2011-06-15 Wyeth Llc Analgetische und entzündungshemmende zusammensetzungen enthaltend celecoxib und ibuprofen
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
DE60120710T2 (de) * 2000-08-18 2007-06-14 Pharmacia Corp. Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib
US8680081B2 (en) * 2000-08-29 2014-03-25 Peter Van Patten Prophylactic treatment of migraine
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
CA2445502A1 (fr) * 2001-05-04 2002-11-14 Merck & Co., Inc. Procede et compositions pour le traitement des migraines
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
CN1633281A (zh) * 2001-09-26 2005-06-29 法马西亚公司 口内崩解的伐地考昔组合物
EP1450769A1 (fr) * 2001-10-10 2004-09-01 Pharmacia Corporation Compositions de valdecoxib a desintegration intra-orale preparees a l'aide d'un procede de sechage par pulverisation
CA2476744A1 (fr) * 2002-03-07 2003-09-12 Novartis Ag Compositions pharmaceutiques solides comprenant du lumiracoxib
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
ATE342722T1 (de) 2003-05-07 2006-11-15 Osteologix As Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
EP2114461A2 (fr) * 2007-01-19 2009-11-11 Mallinckrodt Inc. Ligands de liaison à la cycloxygénase-2 diagnostiques et thérapeutiques
MX2021005967A (es) 2018-11-21 2021-10-13 Tremeau Pharmaceuticals Inc Formas purificadas de rofecoxib, métodos de fabricación y uso.
WO2020210373A1 (fr) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Traitement des fièvres hémorragiques virales avec de l'étoricoxib
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CN1143365A (zh) * 1994-01-10 1997-02-19 麦克弗罗斯特(加拿大)有限公司 作为cox-2抑制剂的苯基杂环类化合物

Also Published As

Publication number Publication date
KR100373622B1 (ko) 2003-07-12
HUP9902889A3 (en) 2002-04-29
PL329940A1 (en) 1999-04-26
AU3004997A (en) 1997-12-09
CA2254061A1 (fr) 1997-11-27
NZ332670A (en) 2000-07-28
CZ373898A3 (cs) 1999-06-16
BG103000A (en) 1999-09-30
SK156798A3 (en) 2000-01-18
CA2254061C (fr) 2003-12-02
NO985342L (no) 1998-11-16
PL188649B1 (pl) 2005-03-31
AR012014A1 (es) 2000-09-27
SK284330B6 (sk) 2005-01-03
CO5050370A1 (es) 2001-06-27
TR199802345T2 (xx) 1999-03-22
EE03746B1 (et) 2002-06-17
US6063811A (en) 2000-05-16
CN1225010A (zh) 1999-08-04
IL126899A (en) 2004-03-28
EP0910368A1 (fr) 1999-04-28
JPH11512754A (ja) 1999-11-02
ID16921A (id) 1997-11-20
EE9800393A (et) 1999-06-15
HUP9902889A2 (hu) 2002-01-28
HRP970262A2 (en) 1998-06-30
PE66998A1 (es) 1998-10-24
IL126899A0 (en) 1999-09-22
IS4891A (is) 1998-11-10
CN1140267C (zh) 2004-03-03
EA199801017A1 (ru) 1999-04-29
WO1997044028A1 (fr) 1997-11-27
KR20000011082A (ko) 2000-02-25
BR9709097A (pt) 1999-08-03
HK1021623A1 (en) 2000-06-23
CZ291463B6 (cs) 2003-03-12
NO985342D0 (no) 1998-11-16
MY116201A (en) 2003-11-28
EA001596B1 (ru) 2001-06-25

Similar Documents

Publication Publication Date Title
DZ2200A1 (fr) Compositions pour un traitement une fois par jour des maladies ayant pour mediateur la 2-cyclooxygenase.
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
EP0801646A4 (fr) Compositions pharmaceutiques pour la prevention et le traitement de maladies du systeme nerveux central
FR15C0070I2 (fr) Composes heteroaromatiques azotes pour le traitement des maladies de cancer
EA200800375A1 (ru) Соединения и способы ингибирования экспрессии vcam-1
DZ3500A1 (fr) Derives de phenethanolamine pour le traitement de maladies respiratoires
MA28289A1 (fr) Immunoglobulines
MA25823A1 (fr) Compositions pour le traitement de l'eau.
EP1578367A4 (fr) Compositions et methodes pour le traitement de maladies liees au systeme immunitaire
BG102241A (bg) Инхибитори на клетъчна адхезия
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
EP1438062A4 (fr) Methodes et compositions pour le traitement de lesions cutanees
OA09478A (fr) "Utilisation de la N-myristoyl-(S)-phénylalaine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation".
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
EP1311261A4 (fr) Medicaments pour le traitement chimiotherapeutique de maladies
MA26950A1 (fr) Nouveaux retinoides pour le traitement de l'emphyseme
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
EP0946178A4 (fr) Traitement combine destine a reduire les risques de maladies cardio-vasculaires
DE69519577D1 (de) Prednisolonmetasulfobenzoatzusammensetzung zur behandlung von entzündungserkrankung des darmes
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
ITTO940748A0 (it) Condotto protesico particolarmente per il trattamento di patologie cardiovascolari.
EP0959879A4 (fr) Therapie photodynamique pour le traitement de l'arthrose
EP1126850A4 (fr) Traitement des affections de la retine